GEN-MKT-18-7897-A
May 8, 2020 | Blogs, Development, Pharma, QA/QC | 0 comments
In my previous blog, I spoke about the FDA recall of angiotensin II receptor blockers like losartan. This recall was due to the presence of genotoxic nitrosamines.
Is a proactive approach the way to mitigate risk?
Recently, the FDA has re-issued the 2018 guidance to industry, “M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk”. Is this going to help? Or should we have a higher focus of qualitative analysis up front?
Companies need to take a look all facets of their supply chain and manufacturing process. They should be able to ensure they can control the active pharmaceutical ingredients (APIs) throughout the process, whether they do it in their own facility or it is outsourced.
How are they going to do this?
Why you need a control strategy
A control strategy is a planned set of controls derived from current product and process understanding that assures process performance and product quality (ICH Q10, Ref. 8).
A control strategy can include, but is not limited to, the following:
How to ensuring better data, by seeing it all
Work previously presented by Prof. Sörgel, at the Institute for Biomedical and Pharmaceutical Research, Nuremberg, Germany on the benefits of this workflow is that with SWATH® Acquisition you are creating a digital record of all the analytes in the sample.
This approach shows:
Watch out for our next blog where we examine some of the analytical challenges of these molecules.You can learn more about how LC-MS/MS solutions can identify, quantify and monitor the required levels of nitrosamine impurities by accessing technical notes and a webinar addressing the characterization and quantification of the genotoxic impurities.
Learn More >
This is part two of an ongoing blog series on genotoxic analysis. Read part one: “What have we learned from the nitrosamine crisis?” and part three: “Developing a method for nitrosamine analysis in pharmaceutical products“.
RUO-MKT-18-11383-A
For decades, SCIEX has been part of bioanalytical innovation, empowering scientists in pharma and biopharma to push the boundaries of sensitivity, accuracy, and throughput. Across complex workflows and increasingly challenging therapeutic modalities.
Trifluoroacetic acid (TFA) is emerging as one of the most concerning ultrashort-chain PFAS in Europe’s food supply – particularly in cereals, a staple consumed daily by millions. A report from PAN Europe reveals a widespread and largely unmonitored contamination trend that raises serious questions about food safety, regulatory blind spots, and future monitoring strategies.
PFAS analysis is complex, but expert guidance doesn’t have to be. In this episode of our ‘Ask the PFAS expert series’, we’re joined by Michael Scherer, Application Lead for Food and Environmental, to answer the most pressing questions in PFAS analysis. From why LC-MS/MS systems are the gold standard for analyzing diverse PFAS compounds, to which EU methods deliver reliable results for drinking water, and to practical steps to prevent contamination, Michael shares actionable insights to help laboratories achieve accuracy, consistency, and confidence in their workflows.
Posted by
You must be logged in to post a comment.
Share this post with your network